American Academy of Allergy, Asthma and Immunology
555 East Wells Street
Suite 1100
Milwaukee
Wisconsin
53202-3823
United States
Tel: 414-272-6071
Fax: 414-272-6070
Website: http://www.aaaai.org/
58 articles about American Academy of Allergy, Asthma and Immunology
-
Late-breaking phase 3 data at 2022 AAAAI Annual Meeting show Dupixent® (dupilumab) significantly reduced itch and hives in patients with chronic spontaneous urticaria
2/26/2022
Detailed results from a Phase 3 trial showed that adding Dupixent® to standard-of-care antihistamines significantly reduced itch and hives at 24 weeks in biologic-naïve patients with chronic spontaneous urticaria compared to antihistamines alone in this investigational setting.
-
Late-breaking data at 2022 AAAAI Annual Meeting show Dupixent® (dupilumab) significantly improved signs and symptoms of eosinophilic esophagitis
2/26/2022
Positive detailed results from a second Phase 3 trial showed that Dupixent® 300 mg weekly significantly improved the signs and symptoms of eosinophilic esophagitis at 24 weeks compared to placebo in patients 12 years and older.
-
Research Presentations at the 2021 Annual AAAAI Meeting Highlight Limitations of Current Food Allergy Treatments and Further Validates Intrommune Therapeutics’ Approach
3/12/2021
Global Allergy Conference Amplifies Need for Safe and Effective Peanut Allergy Therapies
-
Neurelis Announces That Intravail® Licensee, ARS Pharmaceuticals' Intranasal Epinephrine Product, Demonstrates Bioequivalent Exposure To Epinephrine Injectors
5/4/2020
- ARS Pharmaceuticals' lead product, ARS-1 (epinephrine nasal spray) to treat severe allergic reactions, has previously been granted Fast Track designation by the U.S. Food and Drug Administration (FDA) - Neurelis' lead product, VALTOCO® (diazepam nasal spray), approved by the FDA for seizure cluster rescue, also utilizes Intravail® as a key component of its formulation - New data further highlight the permeation enhancement potency of Intravail® for both small and large mole
-
UNC School of Medicine Experts to Present New Research at AAAAI and SRNT Annual Meetings in San Francisco
2/19/2019
The Society for Research on Nicotine and Tobacco (SRNT) conference along with the American Academy of Allergy, Asthma and Immunology (AAAAI) conference are happening this weekend in San Francisco. UNC School of Medicine (SOM) experts will be available for comment on newly released research and trending topics.
-
Aimmune Presents Clinical Data On Phase III Screening And Phase 2 Adherence For AR101 For Peanut Allergy At The 2017 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting
3/6/2017
-
Teva To Present New Respiratory Data At The 2016 Teva Annual Meeting
3/3/2016
-
Baxalta To Showcase Innovation Leadership In Primary Immune Deficiencies During 2016 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting
3/3/2016
-
DBV Tech To Present New Data At The 2016 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting
2/10/2016
-
Aimmune Announces Presentation At The 2016 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting
2/10/2016
-
Antibiotic Overuse Might Be Why So Many People Have Allergies, American Academy of Allergy, Asthma and Immunology (AAAAI) Reveals
9/28/2015
-
DBV Technologies Release: Viaskin Data Presented At American Academy of Allergy, Asthma and Immunology (AAAAI) Meeting Show Safety And Efficacy In The Treatment Of Food Allergies
2/24/2015
-
ADMA Biologics, Inc. Announces Positive Data On Primary And Secondary Endpoints From Its Pivotal Phase III Clinical Trial For RI-002 At The American Academy of Allergy, Asthma and Immunology (AAAAI) Medical Conference
2/23/2015
-
Immunomic Therapeutics To Present Data On Its Proprietary LAMP Vaccine Platform At 2015 American Academy of Allergy, Asthma and Immunology (AAAAI) Meeting
2/20/2015
-
ADMA Biologics, Inc. Announces Data To Be Presented At 2015 American Academy of Allergy, Asthma and Immunology (AAAAI)
2/17/2015
-
Aldeyra Therapeutics Abstract Accepted At 2015 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting
12/16/2014
-
DBV Technologies Release: Presentation And Publication Of Research At American Academy of Allergy, Asthma and Immunology (AAAAI) Demonstrates EPIT(TM)'S Ability To Rebalance The Immune System And Induce A Disease-Modifying Effect
3/5/2014
-
DBV Technologies To Present Key Scientific Publications At The American Academy Of Allergy, Asthma & Immunology (AAAAI) Annual Conference
1/29/2014
-
KaloBios Pharmaceuticals, Inc. Presents Clinical Results With Anti-GM-CSF Antibody in Persistent Asthma Data From KB002 Phase 1/2 Study Presented at the American Academy of Allergy, Asthma and Immunology (AAAAI) Meeting
2/27/2013
-
Dyax Corp. Release: KALBITOR® (ecallantide) Data Presented at American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting
3/6/2012